A CLEARER FUTURE

AIM FOR
CLEAR SKIN

Not an actual patient

A CLEARER FUTURE

RELIEVE THE BURDEN OF ROSACEA1,2

Help your rosacea patients
achieve clearer skin

As a healthcare professional, your role is vital in supporting your patients throughout their rosacea journey, working with them to relieve the physical, social and emotional burden of their disease2

By developing a maintenance plan, you can actively help control their rosacea symptoms, driving them towards achieving clearer skin with the goal of IGA 01,2*

Not an actual patient
quote

“After talking with my dermatologist,
I finally feel like I can help control my
rosacea – it’s liberating!”

outside image of red haired girl smiling and looking in shop window showing mild to moderate roscea on her cdheets and forward
Not an actual patient

The importance of aiming for ‘clear’ (IGA 0) as a treatment goal vs ‘almost clear’ (IGA 1):1,2

Disease impact

Disease impact

Achieving ‘clear’ improves the quality of life for 1 in 2 rosacea patients, significantly more than ‘almost clear’2

Time to relapse

Time to relapse

Rosacea patients who reached ‘clear’ had a longer time to relapse, and when they did relapse, they responded faster to treatment compared to ‘almost clear’2

Patient satisfaction

Patient satisfaction

Rosacea patients who are ‘clear’ tend to say their work productivity is unaffected and have a lower number of doctor visits vs those who are almost ‘clear’2

  pill

Oracea capsules

For rosacea patients, the benefits of ‘clear’ (IGA 0) can
go beyond symptom improvement1,2

*IGA, Investigator’s Global Assessment

savings

How your rosacea patients may save on ORACEA Capsules

Clinical photos

See visible
results

bacterial resistance

How doxycycline
100 mg caused antibiotic resistance 

antibiotic resistance

Limiting the spread of antibiotic resistance

Sign up and

stay up-to-date

For the latest news, research, and insights into papulopustular rosacea, subscribe now! You’ll also receive patient resources and toolkits, helping you treat your patients throughout their rosacea journey

Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

*30 mg immediate release and 10 mg delayed release beads

REFERENCES

1. Schaller M, et al. Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel. British Journal of Dermatology. 2019. doi: 10.1111/ bjd.18420. [Epub ahead of print]. 2. Rosacea: Beyond the visible report. Available at: https://hosted.bmj.com/rosaceabeyondthevisible. Accessed: September 2021